Philips Respironics Introduces a New Level of Intelligence, Control and Convenience for Treating and Managing Sleep Apnea Patients in its Most Advanced CPAP to Date

MURRYSVILLE, Pa., Oct. 7, 2011 /PRNewswire/ -- Philips Respironics, a unit of Royal Philips Electronics (NYSE: PHG, AEX: PHI), is shaping the future of sleep therapy by providing an innovative technology for treating and managing obstructive sleep apnea (OSA) – in its most advanced CPAP (Continuous Positive Airway Pressure) device to date. The new REMstar Pro with AutoIQ is a prime example of an intelligent solution that allows providers and physicians to deliver exceptional care while helping their patients take control of their sleep therapy.

To view the multimedia assets associated with this release, please click: http://www.multivu.com/mnr/51736-philips-respironics-introduces-advanced-cpap-for-managing-sleep-apnea

(Photo: http://photos.prnewswire.com/prnh/20111007/MM81785 )

The new AutoIQ mode has the ability to track a patient's progress over several nights, establish or readjust to an ideal therapy pressure, and check back periodically to reassess and adjust treatment as needed. This is all done without requiring the provider to visit the patient's home.

"Philips Respironics is committed to developing innovations that take us one step closer to making patient success automatic, allowing patients to benefit from better sleep," John Frank, Sr. Vice President, General Manager, Sleep and Respiratory Care, Philips Home Healthcare Solutions. "REMstar Pro with AutoIQ demonstrates our ongoing pledge to providers and their patients to be their ally in better sleep and breathing.  By providing intelligent solutions and advancements in technology, we are shaping the future of sleep therapy."

There are two distinct phases of the AutoIQ mode: Auto-Trial and Auto-Check. The first phase, Auto-Trial, uses the proven Philips Respironics auto algorithm for periods of three days or more, adding up to a total of 30 days, to deliver breath-by-breath therapy and learn the patient's treatment needs. Auto-Trial days can be saved to reassess therapy at a later date should the patient's condition or characteristics change, such as weight gain or a change in sleeping environment. At the end of the Auto-Trial phase, the device analyzes the data to identify and automatically deliver the ideal pressure for that patient. It can also deliver a fixed pressure that has been set by the clinician.

Once the ideal pressure is established for the patient, Auto-Check, the second phase of the AutoIQ mode, checks back every 30 hours to see how the patient is progressing with therapy. This phase determines if a pressure change is needed and automatically adjusts the pressure (within the limits set by the clinician) to meet therapeutic needs.

Throughout the entire process, AutoIQ keeps the care team informed with key compliance information. The REMstar Pro with AutoIQ mode provides new levels of intelligence, control and convenience for sleep therapy.

For more information, visit www.healthcare.philips.com/main/homehealth/sleep/remstarprowithautoiq/

About Royal Philips Electronics

Royal Philips Electronics of the Netherlands (NYSE: PHG, AEX: PHI) is a diversified health and well-being company, focused on improving people's lives through timely innovations. As a world leader in healthcare, lifestyle and lighting, Philips integrates technologies and design into people-centric solutions, based on fundamental customer insights and the brand promise of "sense and simplicity." Headquartered in the Netherlands, Philips employs over 120,000 employees with sales and services in more than 100 countries worldwide. With sales of EUR 22.3 billion in 2010, the company is a market leader in cardiac care, acute care and home healthcare, energy efficient lighting solutions and new lighting applications, as well as lifestyle products for personal well-being and pleasure with strong leadership positions in male shaving and grooming, portable entertainment and oral healthcare. News from Philips is located at www.philips.com/newscenter.

SOURCE Philips Respironics